Compare Crispr Therapeutics AG (CRSP) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wipro Limited — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.99B), while Wipro Limited trades at $1.86 (market cap $18.70B). The key difference: Wipro Limited is far larger — about 3.7× Crispr Therapeutics AG's market cap, and Wipro Limited pays a 10.09% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WIT | |
|---|---|---|
Market Cap | $4.99B | $18.70B |
Sector | Health | Technology |
52-Week High | $76.78 | $3.06 |
52-Week Low | $44.34 | $1.82 |
Enterprise Value | $3.33B | $15.09B |
Dividend Yield | — | 10.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WIT trades at $1.90, up 1.6% with bearish technical signals despite recent AI partnership announcements. The company shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B with a 14.74% margin. Recent earnings misses and weak guidance have tempered investor enthusiasm despite strong cash flow generation and AI initiatives.
WIT presents a cautious outlook with analyst consensus leaning bearish (19% buy vs 33% sell). While valuation appears reasonable (P/E 14.27) and AI partnerships offer growth potential, persistent revenue declines and execution risks in a competitive IT services market warrant careful monitoring. The stock faces near-term pressure from technical weakness and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
